文献速递角膜与眼表疾病

脉冲口服阿奇霉素与6周口服多西环素治疗中重度睑板腺功能障碍:一项随机临床试验

Pulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2023-01-01

该双盲随机临床试验在泰国一家转诊中心纳入137例对保守治疗无反应的中重度睑板腺功能障碍患者,比较口服阿奇霉素(1 g每周一次,共3周)与口服多西环素(200 mg每日,共6周)的疗效与不良事件。结果显示两组在6周和8周时睑板腺功能障碍总评分及眼表疾病指数评分的调整均值差均落在预设等效界值内,阿奇霉素组胃肠道不良事件更少(4.4% vs 15.9%)。

要点

  • 阿奇霉素组与多西环素组在6周和8周时睑板腺功能障碍总评分及眼表疾病指数评分均达到等效。
  • 阿奇霉素组胃肠道不良事件发生率为4.4%,多西环素组为15.9%,风险差11.5%(95%CI 1.6%-21.4%;P=0.03)。
  • 作者认为阿奇霉素给药方案更简短且胃肠道不良事件可能更少,支持其作为多西环素至少6周的替代选择。

核心结论

  • 数据支持阿奇霉素与多西环素在6周和8周随访时对睑板腺功能障碍评分和眼表疾病指数评分的效应等效。
  • 研究未显示阿奇霉素组胃肠道不良事件更多。
  • 阿奇霉素给药次数更少且胃肠道不良事件可能更少,支持其作为多西环素至少6周的替代选择。

研究设计与样本

  • 双盲随机临床试验,在泰国一家转诊中心于2018年9月至2022年5月开展。
  • 纳入对保守治疗无反应的中重度睑板腺功能障碍患者,共137例患者137只眼随机分组,阿奇霉素组68只眼,多西环素组69只眼。
  • 女性占66.4%,平均年龄62.0岁(标准差15.1)。
  • 患者按1:1随机接受口服阿奇霉素(1 g每周一次,共3周)或口服多西环素(200 mg每日,共6周)。
  • 预设睑板腺功能障碍评分和眼表疾病指数评分的等效界值分别为±2和±9。

主要发现

  • 第6周和第8周两组睑板腺功能障碍总评分的调整均值差分别为-0.33(95%CI -1.70至1.03;等效性P=0.01)和0.13(95%CI -1.59至1.84;等效性P=0.02)。
  • 第6周和第8周两组眼表疾病指数评分的调整均值差分别为-1.20(95%CI -5.31至2.91;等效性P<0.001)和-1.59(95%CI -5.73至2.55;等效性P<0.001)。
  • 阿奇霉素组胃肠道不良事件发生率为4.4%,多西环素组为15.9%,风险差11.5%(95%CI 1.6%-21.4%;P=0.03)。

关键数值与推荐

  • 睑板腺功能障碍总评分等效界值为±2,眼表疾病指数评分等效界值为±9。
  • 第6周睑板腺功能障碍总评分调整均值差-0.33(95%CI -1.70至1.03;等效性P=0.01),第8周为0.13(95%CI -1.59至1.84;等效性P=0.02)。
  • 第6周眼表疾病指数评分调整均值差-1.20(95%CI -5.31至2.91;等效性P<0.001),第8周为-1.59(95%CI -5.73至2.55;等效性P<0.001)。
  • 胃肠道不良事件:阿奇霉素组4.4% vs 多西环素组15.9%,风险差11.5%(95%CI 1.6%-21.4%;P=0.03)。

临床怎么用

  • 作者认为,阿奇霉素给药次数更少且胃肠道不良事件可能更少,支持其作为多西环素至少6周的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The treatment of moderate to severe meibomian gland dysfunction (MGD) with oral doxycycline requires a 6-week course of treatment and has frequent adverse effects (AEs), which may be associated with poor compliance. OBJECTIVE: To determine if the AEs of a 3-week course of oral azithromycin were equivalent to the AEs of a 6-week course of oral doxycycline. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted at a referral center in Thailand from September 2018 to May 2022. Participants with moderate to severe MGD judged unresponsive to conservative management were included. INTERVENTIONS: Patients were randomized 1:1 to receive oral azithromycin (1 g once per week for 3 weeks) or oral doxycycline (200 mg daily for 6 weeks). MAIN OUTCOMES AND MEASURES: After initiating therapy, the study team assessed the total MGD score and Ocular Surface Disease Index (OSDI) score at the initial visit, at 6 weeks, and at 8 weeks, and assessed AEs at 6 weeks and 8 weeks. The prespecified equivalence margins for MGD score and OSDI score were set at ±2 and ±9, respectively. RESULTS: A total of 137 eyes from 137 patients were randomized into groups, 68 eyes in the azithromycin group and 69 eyes in the doxycycline group (female, 66.4%; mean age, 62.0 [SD, 15.1] years). The adjusted mean difference of total MGD scores between groups at week 6 and week 8 were -0.33 (95% CI, -1.70 to 1.03; P for equivalence = .01) and 0.13 (95% CI, -1.59 to 1.84; P for equivalence = .02), respectively. The adjusted mean difference of OSDI between groups score at week 6 and week 8 was -1.20 (95% CI, -5.31 to 2.91; P for equivalence < .001) and -1.59 (95% CI, -5.73 to 2.55; P for equivalence < .001), respectively. In addition, patients treated with azithromycin had fewer gastrointestinal AEs (4.4% vs 15.9%; risk difference, 11.5%; 95% CI 1.6%-21.4%; P = .03). CONCLUSIONS AND RELEVANCE: These data support an equivalency of effects of azithromycin as compared with doxycycline for MGD score and OSDI score at both follow-up times. The study did not show more gastrointestinal AEs in the azithromycin group. The reduced dosing and potentially fewer gastrointestinal AEs associated with azithromycin support its use as an alternative to doxycycline for at least 6 weeks. TRIAL REGISTRATION: ThaiClinicalTrials.org Identifier: TCTR20180810001.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Upaphong P, Tangmonkongvoragul C, Phinyo P, et al. Pulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 36951835. doi:10.1001/jamaophthalmol.2023.0302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。